tag:blogger.com,1999:blog-9551150.post1122937205916790630..comments2024-03-28T01:27:23.408-04:00Comments on Health Care Renewal: Knee Deep in the Hoopla - "A Triumph of Medical Technology" Sans Evidence of Superiority from Published Randomized Double Blind Controlled TrialsRoy M. Poses MDhttp://www.blogger.com/profile/00497209843184497847noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-9551150.post-81746574323679356042014-06-18T11:41:22.188-04:002014-06-18T11:41:22.188-04:00Anonymous of 18 June, 2014,
Yes, and your point i...Anonymous of 18 June, 2014,<br /><br />Yes, and your point is?<br /><br />How valid is POSITRON? Does it have major methodologic biases? What about outcomes other than SVR12? What about adverse events? Who were the patients and how generalizable are results.<br /><br />Note that I am now hardly the only one raising concerns that in general the evidence from clinical research supporting Roy M. Poses MDhttps://www.blogger.com/profile/00497209843184497847noreply@blogger.comtag:blogger.com,1999:blog-9551150.post-64728519588015946132014-06-18T10:29:58.912-04:002014-06-18T10:29:58.912-04:00POSITRON results were published in NEJM 4/23/2013 ...POSITRON results were published in NEJM 4/23/2013 (dated 5/16/2013). The study was published simultaneously with the FUSION study.<br />POSITRON/FUSION studied patients with genotype 2 and 3 Hep C, where response rates using Sovaldi seem to be about the same in other studies (all conducted by Gilead) as found in POSITRON/FUSION.<br />The best results come in genotype 1 patients at > 90% SVR12.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-9551150.post-79418075422031475662014-04-21T11:30:42.822-04:002014-04-21T11:30:42.822-04:00Thanks so much, you are asking the right questions...Thanks so much, you are asking the right questions!Anonymousnoreply@blogger.com